Clinical trials: Bronchial Neoplasms
Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC )
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.
- Conditions
- Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma
- Trial name
- NCT07914764
- Testing
- Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Non Small Cell Lung Cancer
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients…
- Trial name
- NCT05641493
- Testing
- HLX208+HLX10
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Henlius Biotech
Lung Cancer, Non-small Cell
Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC
Lung cancer (LC) remains a leading cause of death among cancers worldwide. Though radiotherapy is one of the most frequently used treatments, it increases side-effects (pain, fatigue) and inflammation, possibly leading to further…
- Trial name
- NCT03553485
- Testing
- Transcutaneous vagus nerve stimulation, Radiotherapy
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Vrije Universiteit Brussel
Lung Cancer, Non-Small Cell Lung Cancer
Molecular Profiling Project
In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype in the local population.
- Trial name
- NCT04025515
- Where
- 10 sites in Brunei, Hong Kong and 4 more
- Volunteers
- 500 people
- Sponsor
- National Cancer Centre, Singapore
NSCLC Stage IIIA/B
Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)
Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)
- Trial name
- NCT02118415
- Testing
- Hsp70-peptide TKD/IL-2 activated, autologous NK cells
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Technical University of Munich
Non-Small Cell Lung Cancer
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to durvalumab will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT02673814
- Testing
- durvalumab, bavituximab
- Sponsor
- Peregrine Pharmaceuticals
Health Status Unknown, Lung Cancer
Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung Cancer
RATIONALE: Environmental exposure and genetic predisposition may affect the risk of developing cancer later in life. Learning about genetic markers and the long-term effects of environmental exposure may help the study of lung…
- Trial name
- NCT00503958
- Testing
- DNA methylation analysis, DNA stability analysis, gene expression analysis
- Where
- 5 sites in United Kingdom
- Volunteers
- 8,300 people, healthy volunteers welcome
- Sponsor
- University of Liverpool Cancer Research Centre
Small Cell Lung Cancer
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent small cell lung cancer after failure of anti-PD-1/PD-L1 Monoclonal…
- Trial name
- NCT06500026
- Testing
- BL-B01D1, Topotecan
- Where
- China
- Volunteers
- 722 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lung Cancer, Non-Small Cell, Lung Cancer, Small Cell
The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
The goal of this prospective, multi-centre, randomised controlled clinical study is to evaluate the diagnostic efficacy and safety of nCLE guided lung biopsy in patients with for peripheral lung nodules under the assistance of…
- Trial name
- NCT06739421
- Testing
- nCLE-NB-rEBUS-forcep biopsy, nCLE-NB-rEBUS-TBCB, NB-rEBUS-forcep biopsy
- Where
- China
- Volunteers
- 1,040 people
- Sponsor
- China-Japan Friendship Hospital
Non-Small Cell Lung Cancer, NSCLC
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Trial name
- SHERLOC (NCT02387216)
- Testing
- MM-121, Docetaxel
- Where
- 35 sites in United States, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Elevation Oncology
Non-Small Cell Lung Cancer
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung…
- Trial name
- NCT03594747
- Testing
- Tislelizumab, Paclitaxel, Nab-paclitaxel
- Where
- 43 sites in China
- Volunteers
- 360 people
- Sponsor
- BeiGene
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients…
- Trial name
- RESONATE™ (NCT01578707)
- Testing
- ofatumumab, ibrutinib
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 391 people
- Sponsor
- Pharmacyclics LLC.
Carcinoma, Non-Small-Cell Lung
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)
To investigate the maximum tolerated dose of BIBF 1120, safety and pharmacokinetics in escalating doses administered with Vinorelbine i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).
- Trial name
- VENUS-1 (NCT01684111)
- Testing
- BIBF 1120, Vinorelbine
- Where
- 4 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
This is a multi-center, non-interventional, study with the aim to access routine practice of diagnostic and treatment approaches in patients with NSCLC and SCLC in 50 largest oncology centers in Russian Federation.
- Trial name
- PASSAT (NCT05887011)
- Where
- 37 sites in Russia
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS
This is a local, prospective, non-interventional, regulatory postmarketing surveillance study. The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study…
- Trial name
- KOREA-PLUS (NCT03918304)
- Where
- 10 sites in South Korea
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
The purpose of this study is to test the drug Bortezomib to see how well it works. The investigators want to find out what effects, good or bad, it has on patients with a limited smoking history or who have a specific mutation…
- Trial name
- NCT01833143
- Testing
- Bortezomib, Acyclovir
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Non Small Cell Lung Cancer
Randomized Gefitinib Trial
Patients with locally advanced (IIIB with effusion) or metastatic non-small cell lung cancer (NSCLC), EGFR FISH positive, candidate for a first-line platinum-based chemotherapy will be considered eligible for the trial.
- Trial name
- RANGE (NCT00807066)
- Testing
- Gefitinib, Platinum
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Fondazione Humanitas per la Ricerca
Non Small Cell Lung Cancer
Understanding Evidence-Based Practice Patterns in Advanced NSCLC
The overarching objective of this study is to close clinical knowledge and performance gaps by providing oncology clinicians with the latest advances and emerging research in the evidence-base and personalized treatment of…
- Trial name
- NCT03107156
- Testing
- Carevive CPS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Carevive Systems, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.